[Finalist] Finnadvance

Contents

Finnadvance provides a human-like biomimetic platform to biotech/pharma for drug R&D to reduce animal testing and decrease 26% total costs of drug discovery. Drugs have different effects on conventional 2D cell cultures and animals versus humans. 90% of drugs validated in pre-clinical models and animals fail during transition to human clinical trials.
Finnadvance main target market, in-vitro toxicology testing market, was valued at $15.3 bn in 2019 and projected to reach $30.9 bn by 2027. Their direct accessible market of Cell culture technology dominated the in-vitro toxicology testing market with a share of 41.7% in 2019. Finnadvance is aiming to be this
category leader by replacing the current conventional 2D products.
Finnadvance is led by an expert team of engineers and life science researchers which published articles and patents.

Profile

Prateek Singh is an engineer and a biochemist with more than 12 years of research experience.
Winning research projects around the world, he decided to transfer the technologies he has developed to a deeptech startup.
Being awarded the prestigious Horizon 2020 EU funding as a 1-man company has put him in the forefront of medtech and healthtech scenario in Europe.